Medifast (NYSE:MED) Director Acquires $31,325.00 in Stock

Posted by George Bondi on May 15th, 2026

Medifast Inc (NYSE:MED – Get Free Report) Director Scott Schlackman acquired 2,500 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the acquisition, the director owned 30,549 shares in the company, valued at approximately $382,778.97. This trade represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Scott Schlackman also recently made the following trade(s):

On Friday, May 8th, Scott Schlackman bought 2,500 shares of Medifast stock. The shares were bought at an average price of $12.65 per share, for a total transaction of $31,625.00.

Medifast Stock Performance

Shares of NYSE:MED opened at $12.59 on Friday. The company has a market cap of $139.96 million, a P/E ratio of -6.88 and a beta of 0.55. Medifast Inc has a one year low of $9.22 and a one year high of $15.46. The business’s 50-day simple moving average is $10.74 and its 200 day simple moving average is $11.09.

Medifast (NYSE:MED – Get Free Report) last announced its earnings results on Monday, May 4th. The specialty retailer reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.36. The business had revenue of $76.04 million for the quarter, compared to the consensus estimate of $69.20 million. Medifast had a negative return on equity of 4.80% and a negative net margin of 5.78%.Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. Analysts predict that Medifast Inc will post -2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings downgraded Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Finally, Stephens dropped their target price on Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, February 19th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Medifast has a consensus rating of “Reduce” and a consensus target price of $12.00.

View Our Latest Stock Analysis on Medifast

Institutional Investors Weigh In On Medifast

A number of hedge funds have recently bought and sold shares of MED. BNP Paribas Financial Markets grew its stake in Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after purchasing an additional 1,187 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Medifast during the 3rd quarter valued at approximately $37,000. Intesa Sanpaolo Wealth Management acquired a new stake in Medifast during the 4th quarter valued at approximately $47,000. State of Wyoming acquired a new stake in Medifast during the 4th quarter valued at approximately $59,000. Finally, Strs Ohio acquired a new stake in Medifast during the 1st quarter valued at approximately $78,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

Medifast Company Profile

(Get Free Report)

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.